International Journal of Radiation Oncology*Biology*Physics 2013-11-15

Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplant

Ji Hyun Kim, Anthony Stein, Nicole Tsai, Timothy E. Schultheiss, Joycelynne Palmer, An Liu, Joseph Rosenthal, Stephen J. Forman, Jeffrey Y.C. Wong

Index: Int. J. Radiat. Oncol. Biol. Phys. 89(1) , 75-81, (2014)

Full Text: HTML

Abstract

Purpose Approximately 5-20% of patients can develop extramedullary (EM) relapse after total body irradiation (TBI) containing hematopoietic cell transplant (HCT). While total marrow and lymphoid irradiation (TMLI) provides a more conformally targeted radiotherapy for patients, organ sparing has the potential to place the patient at a higher risk for EM relapse compared to TBI. This study evaluates EM relapse in patients treated with TMLI at our institution.

Related Compounds

Structure Name/CAS No. Articles
Etoposide Structure Etoposide
CAS:33419-42-0
Busulfan Structure Busulfan
CAS:55-98-1
Fludarabine Structure Fludarabine
CAS:21679-14-1
melphalan Structure melphalan
CAS:148-82-3
Vidarabine Structure Vidarabine
CAS:5536-17-4